Log in to save to my catalogue

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2453158560

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

Publication information

Publisher

United States: Massachusetts Medical Society

More information

Scope and Contents

Contents

In a double-blind, randomized, controlled trial, 95 patients with MERS in Saudi Arabia received recombinant interferon beta-1b plus lopinavir–ritonavir or placebo for 14 days. Active treatment led to improved survival at 90 days when initiated within 7 days after illness onset.

Alternative Titles

Full title

Interferon Beta-1b and Lopinavir–Ritonavir for Middle East Respiratory Syndrome

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2453158560

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2453158560

Other Identifiers

ISSN

0028-4793

E-ISSN

1533-4406

DOI

10.1056/NEJMoa2015294

How to access this item